World Library  


Add to Book Shelf
Flag as Inappropriate
Email this Book

Benign Prostatic Hyperplasia Bph Management in Primary Care: Screening and Therapy

By Department of Veterans Affairs (US)

Click here to view

Book Id: WPLBN0003913598
Format Type: PDF eBook :
File Size:
Reproduction Date: 2015

Title: Benign Prostatic Hyperplasia Bph Management in Primary Care: Screening and Therapy  
Author: Department of Veterans Affairs (US)
Volume:
Language: English
Subject: Science, Medical Science, Non Fiction
Collections: Periodicals: Journal and Magazine Collection, National Center for Biotechnology Information
Historic
Publication Date:
Publisher: National Center for Biotechnology Information

Citation

APA MLA Chicago

Veterans Affairs (Us), D. O. (n.d.). Benign Prostatic Hyperplasia Bph Management in Primary Care: Screening and Therapy. Retrieved from http://www.netlibrary.net/


Description
Description: Benign prostatic hyperplasia (BPH) causes urinary hesitancy and intermittency, weak urine stream, nocturia, frequency, urgency, and the sensation of incomplete bladder emptying. These symptoms, collectively called “lower urinary tract symptoms,” or LUTS, can significantly reduce quality of life. Men with no symptoms or mild symptoms (AUA Symptom Index [SI] score of <7 points), and those who tolerate moderate symptoms well, may be managed without pharmacotherapy (“watchful waiting”). For those who have moderate or severe symptoms, medical treatments include alpha-1-selective adrenergic receptor (a-1-AR) antagonists, 5-alpha-reductase inhibitors (5-aRIs), or a combination therapy with one drug from each of these classes. This report addresses the following questions about treatment for BPH: For patients with BPH, what are the comparative benefits, harms, and efficacy of combination therapy with a 5-alpha-reductase inhibitor plus an alpha blocker versus either treatment alone? What are the comparative efficacy and harms of alpha-1-adrenergic antagonists? Are there subgroups of patients based on demographics (age, racial groups), other medications, or co-morbidities for which one treatment is more effective or associated with fewer adverse events?

Table of Contents
TOC : EXECUTIVE SUMMARY -- INTRODUCTION -- METHODS -- RESULTS -- SUMMARY -- REFERENCES -- APPENDIX A METHODS FOR EVIDENCE SYNTHESIS -- APPENDIX B TRIALS COMPARING ALPHA ANTAGONISTS

 

Click To View

Additional Books


  • Atopic Eczema in Children: Management of... (by )
  • National Center for Biotechnology Inform... (by )
  • A Systematic Evidence Review of Non-phar... (by )
  • The Role of the Chemical Sciences in Fin... (by )
  • Neuroscience Biomarkers and Biosignature... (by )
  • Stable Angina: Methods, Evidence & Guida... (by )
  • Closing the Quality Gap: a Critical Anal... (by )
  • Eos 2D/3D X-ray Imaging System: a System... (by )
  • Self-measured Blood Pressure Monitoring:... (by )
  • Alzheimer's Diagnostic Guideline Validat... (by )
  • Digital Infrastructure for the Learning ... (by )
  • Closing the Quality Gap: a Critical Anal... (by )
Scroll Left
Scroll Right

 



Copyright © World Library Foundation. All rights reserved. eBooks from World Library are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.